​

Laurus Labs Limited

NSEI:LAURUSLABS Stock Report

Market Cap: ₹419.0b

Laurus Labs (LAURUSLABS) Stock Overview

Manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. More details

LAURUSLABS fundamental analysis
Snowflake Score
Valuation0/6
Future Growth4/6
Past Performance4/6
Financial Health5/6
Dividends1/6

Rewards

Earnings are forecast to grow 32.31% per year

Earnings grew by 123.2% over the past year

Risk Analysis

Has a high level of debt


LAURUSLABS Community Fair Values

Create Narrative

See what 13 others think this stock is worth. Follow their fair value or set your own to get alerts.

LAURUSLABS logo
Laurus Labs
AN
AnalystConsensusTarget
Consensus Narrative from 13 Analysts

Advanced Bio Catalysis And Flow Chemistry Will Strengthen Clinical Pipeline

Key Takeaways Advanced technology platforms and manufacturing expansion are set to secure growth with Big Pharma, enhancing revenue and net margins. Diversification from ARV reliance and investment in enzyme engineering are strategic moves projected to drive revenue growth and improve margins.
View narrative
₹564.31
FV
37.6% overvalued intrinsic discount
13.56%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
12users have followed this narrative
about 1 month ago author updated this narrative
LAURUSLABS logo
Laurus Labs
AN
AnalystHighTarget
Consensus Narrative from 13 Analysts

Expanding CDMO Pipeline Will Tap Global Secular Demand

Key Takeaways Strategic advances in biocatalysis, CDMO pipeline growth, and supply chain resilience position Laurus Labs for substantial market share gains and margin outperformance in multiple sectors. Diversification into advanced therapies, animal health, and crop sciences, along with robust capacity and compliance, accelerates growth across global healthcare and non-human markets.
View narrative
₹750.00
FV
3.5% overvalued intrinsic discount
17.70%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
2 days ago author updated this narrative
View Laurus Labs Community

Laurus Labs Limited Competitors

Price History & Performance

Summary of share price highs, lows and changes for Laurus Labs
Historical stock prices
Current Share Price₹776.25
52 Week High₹779.45
52 Week Low₹414.00
Beta0.80
1 Month Change20.90%
3 Month Change34.01%
1 Year Change63.61%
3 Year Change57.85%
5 Year Change522.09%
Change since IPO707.92%

Recent News & Updates

Investors Shouldn't Be Too Comfortable With Laurus Labs' (NSE:LAURUSLABS) Earnings

Jun 11
Investors Shouldn't Be Too Comfortable With Laurus Labs' (NSE:LAURUSLABS) Earnings

Laurus Labs (NSE:LAURUSLABS) Has A Pretty Healthy Balance Sheet

May 19
Laurus Labs (NSE:LAURUSLABS) Has A Pretty Healthy Balance Sheet

Laurus Labs Limited Just Recorded A 7.2% EPS Beat: Here's What Analysts Are Forecasting Next

Apr 27
Laurus Labs Limited Just Recorded A 7.2% EPS Beat: Here's What Analysts Are Forecasting Next

Recent updates

Investors Shouldn't Be Too Comfortable With Laurus Labs' (NSE:LAURUSLABS) Earnings

Jun 11
Investors Shouldn't Be Too Comfortable With Laurus Labs' (NSE:LAURUSLABS) Earnings

Laurus Labs (NSE:LAURUSLABS) Has A Pretty Healthy Balance Sheet

May 19
Laurus Labs (NSE:LAURUSLABS) Has A Pretty Healthy Balance Sheet

Laurus Labs Limited Just Recorded A 7.2% EPS Beat: Here's What Analysts Are Forecasting Next

Apr 27
Laurus Labs Limited Just Recorded A 7.2% EPS Beat: Here's What Analysts Are Forecasting Next

Laurus Labs Limited (NSE:LAURUSLABS) Not Flying Under The Radar

Apr 07
Laurus Labs Limited (NSE:LAURUSLABS) Not Flying Under The Radar

Laurus Labs Limited Beat Revenue Forecasts By 7.0%: Here's What Analysts Are Forecasting Next

Jan 27
Laurus Labs Limited Beat Revenue Forecasts By 7.0%: Here's What Analysts Are Forecasting Next
author-image

CDMO Expansion May Impact Near-Term Margins But Pave Way For Future Revenue Streams

Heavy investment in CDMO and microbial precision initiatives may lead to revenue delays and short-term margin compression due to underutilized assets.

These 4 Measures Indicate That Laurus Labs (NSE:LAURUSLABS) Is Using Debt Extensively

Jan 25
These 4 Measures Indicate That Laurus Labs (NSE:LAURUSLABS) Is Using Debt Extensively

Laurus Labs Limited's (NSE:LAURUSLABS) P/S Is On The Mark

Jan 03
Laurus Labs Limited's (NSE:LAURUSLABS) P/S Is On The Mark

Laurus Labs (NSE:LAURUSLABS) Is Due To Pay A Dividend Of ₹0.40

Oct 28
Laurus Labs (NSE:LAURUSLABS) Is Due To Pay A Dividend Of ₹0.40

Laurus Labs (NSE:LAURUSLABS) Takes On Some Risk With Its Use Of Debt

Oct 26
Laurus Labs (NSE:LAURUSLABS) Takes On Some Risk With Its Use Of Debt

Shareholder Returns

LAURUSLABSIN PharmaceuticalsIN Market
7D7.1%1.6%0.009%
1Y63.6%10.6%-1.1%

Return vs Industry: LAURUSLABS exceeded the Indian Pharmaceuticals industry which returned 10.6% over the past year.

Return vs Market: LAURUSLABS exceeded the Indian Market which returned -1.1% over the past year.

Price Volatility

Is LAURUSLABS's price volatile compared to industry and market?
LAURUSLABS volatility
LAURUSLABS Average Weekly Movement4.3%
Pharmaceuticals Industry Average Movement5.9%
Market Average Movement6.0%
10% most volatile stocks in IN Market8.7%
10% least volatile stocks in IN Market4.1%

Stable Share Price: LAURUSLABS has not had significant price volatility in the past 3 months compared to the Indian market.

Volatility Over Time: LAURUSLABS's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20056,167Satyanarayana Chavawww.lauruslabs.com

Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs and oral solid formulations for advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It also provides biotechnology services used in the nutraceutical, dietary supplements, alternate food proteins, and cosmeceutical products.

Laurus Labs Limited Fundamentals Summary

How do Laurus Labs's earnings and revenue compare to its market cap?
LAURUSLABS fundamental statistics
Market cap₹419.04b
Earnings (TTM)₹3.58b
Revenue (TTM)₹55.54b
116.9x
P/E Ratio
7.5x
P/S Ratio

Is LAURUSLABS overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
LAURUSLABS income statement (TTM)
Revenue₹55.54b
Cost of Revenue₹25.89b
Gross Profit₹29.65b
Other Expenses₹26.07b
Earnings₹3.58b

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)6.64
Gross Margin53.39%
Net Profit Margin6.45%
Debt/Equity Ratio58.5%

How did LAURUSLABS perform over the long term?

See historical performance and comparison

Dividends

0.2%
Current Dividend Yield
18%
Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/07/07 17:55
End of Day Share Price 2025/07/07 00:00
Earnings2025/03/31
Annual Earnings2025/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Laurus Labs Limited is covered by 20 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Nitin BhasinAmbit Capital
null nullAntique Stockbroking Ltd.
Vijayaraghavan SwaminathanAvendus Spark